Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557899 | 1.00 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL28429395 | 0.97 | KMT2A (0.71) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31270657 | 0.97 | KMT2A (0.71) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29397906 | 0.88 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29423575 | 0.88 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL178687 | 0.88 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL12291373 | 0.86 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL18290276 | 0.86 | KMT2A (0.65) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL3140809 | 0.84 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL13525077 | 0.84 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699126-A | G L P-1 derivative and application thereof | 诺和诺德股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-103403177-B | Sensor | 弗里堡大学 | 2018-08-14 | — | — | CN | disclosed |
| CN-107108714-A | Derivatives of GLP 1 and application thereof | 诺和诺德股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-106999602-A | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-103003300-B | Peptide conjugates of GLP-1 receptor agonists and gastrin and uses thereof | 西兰制药公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-106536547-A | GLP-1/glucagon receptor co-agonists for medical use | 诺和诺德股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-8598314-B2 | Peptide-peptidase-inhibitor conjugates and methods of making and using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| CN-101784562-A | insulin analogues with an acyl and aklylene glycol moiety | NOVO NORDISK AS | 2010-07-21 | — | — | CN | disclosed |
| EP-2195034-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | Amylin Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009042922-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | KMT2A 3649/4885EPHX2 3443/4885CASP3 167/4885 |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | KMT2A 2595/4885EPHX2 1866/4885CASP3 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.